每周服用西马鲁肽可减少成人酒精使用障碍患者的渴求

The Brown University Psychopharmacology Update Pub Date : 2025-04-29 DOI:10.1002/pu.31307

{"title":"每周服用西马鲁肽可减少成人酒精使用障碍患者的渴求","authors":"","doi":"10.1002/pu.31307","DOIUrl":null,"url":null,"abstract":"Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry.","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 6","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Weekly semaglutide reduces craving in adults with alcohol use disorder\",\"authors\":\"\",\"doi\":\"10.1002/pu.31307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry.\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 6\",\"pages\":\"1-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31307\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31307","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

一项为期9周的随机试验发现，与安慰剂相比，每周剂量的胰高血糖素样肽1 （GLP-1）受体激动剂semaglutide可减少酒精使用障碍（AUD）成人患者的酒精渴望。与安慰剂相比，使用西马鲁肽也能改善部分但不是全部的酒精使用结果。研究结果于2月12日在网上发表。2025年，《美国医学会精神病学》。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Weekly semaglutide reduces craving in adults with alcohol use disorder

Weekly doses of the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide resulted in reduced alcohol craving relative to placebo in adults with alcohol use disorder (AUD), a 9-week randomized trial has found. Use of semaglutide also resulted in improvement in some but not all alcohol use outcomes compared with placebo. Study results were published online Feb. 12. 2025, in JAMA Psychiatry.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Brown University Psychopharmacology Update

自引率

0.00%

发文量